Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tempest Therapeutics, Inc.

NASDAQ: TPST · Life Sciences · 12 alerts · CIK 1544227

Share price
$0.3418Close, Nov 16
Market cap
$6.83M
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tempest Therapeutics, Inc. filings on SEC EDGAR ↗

4:06 PM ET 8-K
Research Collaboration

Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M

Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.

Value
$5M
Counterparty
Factor Bioscience Inc.
Term
annual
5:06 PM ET 8-K
Research Collaboration

Tempest Therapeutics Research Collaboration with Heibei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics entered into an exclusive collaboration and option agreement with Heibei Senlang Biotechnology to develop and commercialize an in vivo CAR-T technology platform worldwide, excluding Greater China. Tempest paid an option fee of approximately $0.447 million for a four-month window to license the technology, which includes a Phase 1 dual-targeting candidate for multiple myeloma. The deal establishes Tempest as a multi-platform in vivo CAR-T company, combining Senlang's lentiviral vector platform with Tempest's existing LNP delivery technology.

Counterparty
Heibei Senlang Biotechnology Co., Ltd.
Term
4 month option period

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.